Litcius/Paper detail

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

Terry J. Fry, Nirali N. Shah, Rimas J. Orentas, Maryalice Stetler‐Stevenson, Constance M. Yuan, Sneha Ramakrishna, Pamela L. Wolters, Staci Martin, Cindy Delbrook, Bonnie Yates, Haneen Shalabi, Thomas J. Fountaine, Jack F. Shern, Robbie G. Majzner, David F. Stroncek, Marianna Sabatino, Yang Feng, Dimiter S. Dimitrov, Ling Zhang, Sang M. Nguyen, Haiying Qin, Boro Dropulić, Daniel W Lee, Crystal L. Mackall

2017Nature Medicine1,349 citationsDOI

Topics & Concepts

CD22CD19ImmunotherapyMedicineAntigenChimeric antigen receptorImmunologyB cellInternal medicineRefractory (planetary science)Cancer researchBiologyAntibodyImmune systemAstrobiologyCAR-T cell therapy researchImmune Cell Function and InteractionSilicon Carbide Semiconductor Technologies
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy | Litcius